Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities research analysts at HC Wainwright raised their FY2026 earnings estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of $0.92 per share for the year, up from their previous forecast of $0.91. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share.
Fennec Pharmaceuticals Stock Performance
Shares of Fennec Pharmaceuticals stock opened at C$11.34 on Wednesday. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$11.49. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$218.69 million, a PE ratio of -192.10 and a beta of 0.25. The stock's fifty day simple moving average is C$8.30 and its 200 day simple moving average is C$8.46.
Insider Buying and Selling
In other Fennec Pharmaceuticals news, Director Jeffrey Hackman acquired 15,000 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, for a total transaction of C$146,580.00. Also, Director Rostislav Christov Raykov sold 10,000 shares of the business's stock in a transaction on Friday, April 4th. The stock was sold at an average price of C$7.46, for a total transaction of C$74,550.00. In the last ninety days, insiders sold 35,645 shares of company stock valued at $316,021. Company insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
